The FDA recently released results of a review that found an increased risk of aortic ruptures or tears with the use of fluoroquinolones.  As part of the safety warning, the FDA has recommendations for providers, including avoidance of fluoroquinolones in patients with a history of aortic aneurysm or those at risk for an aneurysm; to provide counseling for patients regarding the symptoms of aortic aneurysm and the need to seek emergency treatment; and to reserve the use of fluoroquinolones for patients without other antibiotic treatment options. Fluoroquinolones, like Cipro or Levaquin, are a commonly used antibiotic in gastroenterology and many other fields. The risk of tendonitis and even tendon rupture is well recognized.

See the FDA statement here.